Prognosis of T1G3 bladder cancer patients after the intravesical adjuvant bacillus Calmette-Gue´rin (BCG) immunotherapy.

Abstract

According to our retrospective data BCG maintenance intravesical treatment can decrease the recurrence and progression risk of T1G3 urothelial bladder cancer and prolong the overall and tumor specific survival.

Keywords

• BCG
• progression
• recurrence
• maintenance BCG treatment
• urothelial T1G3 bladder cancer